不可逆电穿孔联合减量放疗治疗中危前列腺癌的I期试验
本研究为前瞻性I期试验,纳入10例MRI可见局灶指数病灶的中危前列腺癌患者,行不可逆电穿孔后减量放疗(32.5 Gy/5次)。12个月活检均无残留病灶,PSA显著下降,无严重不良事件,患者报告结局无临床意义恶化。
要点
- RTIRE治疗后12个月穿刺活检全部(10/10)未见残留病灶
- PSA中位数从基线7.65 ng/mL降至3个月0.98 ng/mL,12个月维持0.56 ng/mL
- 27例不良事件均为1级或2级,无严重不良事件
核心结论
- 中危前列腺癌患者接受不可逆电穿孔联合减量放疗(32.5 Gy/5次)可行,12个月活检无残留,无严重不良事件。
研究设计与样本
- 前瞻性研究,2022年5月至2024年4月,纳入10例MRI可见局灶指数病灶(分级组2或3)的中危前列腺癌患者,中位年龄66岁[IQR,61–72岁]。
- 入组后行不可逆电穿孔联合减量放疗(32.5 Gy/5次),随访3、6、9、12个月,主要终点为入组可行性,次要终点包括早期肿瘤控制、生存质量结局和不良事件。
关键影像表现/征象
- 入组标准要求MRI上可见局灶指数病灶,分级组为2级或3级。
- 12个月随访时穿刺活检显示100%(10/10)参与者无残留病灶。
诊断标准与关键数值
- 主要终点为入组可行性,10例患者均成功完成RTIRE治疗。
- 12个月活检无残留病灶比例为100%(10/10)。
- PSA中位数从基线7.65 ng/mL降至3个月0.98 ng/mL(P = .002),12个月为0.56 ng/mL(P = .002 vs 基线)。
临床应用与阅片要点
- MRI可见局灶指数病灶(分级组2或3)是中危前列腺癌患者接受RTIRE的入组影像条件。
- 治疗后12个月穿刺活检可作为局灶治疗后的肿瘤控制评估手段。
局限性
- 样本量仅10例,为单臂I期试验。
- 随访时间仅至12个月,长期肿瘤控制与安全性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Irreversible electroporation (IRE) is a nonthermal local therapy for prostate cancer (PCa). However, the feasibility, outcomes, and safety of reduced-dose radiation therapy (RT) following IRE (RTIRE) for the treatment of intermediate-risk PCa are unknown. Purpose To assess the feasibility of RTIRE for the treatment of intermediate-risk PCa. Materials and Methods This was a prospective study from May 2022 to April 2024 and included participants with intermediate-risk PCa with a focal index lesion (grade group 2 or 3 disease) visible at MRI. Participants underwent RTIRE (to 32.5 Gy in five fractions) with follow-up at 3, 6, 9, and 12 months. The primary end point was enrollment feasibility. Secondary end points included early oncologic control, quality-of-life outcomes, and adverse events. The Wilcoxon rank-sum test was used to compare continuous values at different time points. Results A total of 10 men (median age, 66 years [IQR, 61-72 years]) successfully completed RTIRE. At 12 months, no residual disease was detected at biopsy in 100% (10 of 10) of participants. Median prostate-specific antigen level decreased from baseline (7.65 ng/mL) to 3 months (0.98 ng/mL; P = .002) and remained stable at 12 months (0.56 ng/mL; P = .002 vs baseline). Median Expanded Prostate Cancer Index Composite for Clinical Practice score increased from baseline (3.5 [IQR, 3-8]) to 6 months (13 [IQR, 9-19]; P = .02), returning to near baseline at 12 months (6 [IQR, 5-15.75]; P = .05). International Index of Erectile Function score decreased from baseline (median, 23.5) to 6 months (median, 12; P = .02), with recovery by 12 months (median, 22; P = .16 vs baseline). Median International Prostate Symptom Score was stable at 12 months (P = .56 vs baseline). No severe adverse events occurred (100% [27 of 27] of adverse events were grade 1 or 2). Conclusion Treatment of participants with intermediate-risk PCa with RTIRE was feasible and showed no clinically meaningful decline in patient-reported outcomes and no severe adverse events. Clinical trial registration no. NCT05345444 © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Nezami and Unger in this issue.
引用
- McClure, Wang, Ballman, et al. Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial. Radiology. 2026. PMID: 42517770. doi:10.1148/radiol.250848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。